News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Insights
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Advertise
Talent Solutions
Post Jobs
Submit a Press Release
Submit an Event
SUBSCRIBE
Menu
SUBSCRIBE
Show Search
News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Insights
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Advertise
Talent Solutions
Post Jobs
Submit a Press Release
Submit an Event
Search Query
Submit Search
News
Business
Deals
Merck & Co., Inc. Announces Completion of Acquisition Of Sirna Therapeutics, Inc.
December 29, 2006
|
1 min read
Twitter
LinkedIn
Facebook
Email
Print
WHITEHOUSE STATION, N.J.--(BUSINESS WIRE)--Merck & Co., Inc. (NYSE: MRK) today announced that it has successfully completed the acquisition of Sirna Therapeutics, Inc. (NASDAQ: RNAI) in a cash transaction which closed in the fourth quarter of 2006.
Twitter
LinkedIn
Facebook
Email
Print
Mergers & acquisitions
MORE ON THIS TOPIC
Licensing
Lilly pens another deal, inking up to $5.9B oncology pact with Stipple
November 17, 2026
·
1 min read
·
Annalee Armstrong
Funding
Marrow Therapeutics debuts with $173M to tackle blood disorders in vivo
November 17, 2026
·
2 min read
·
Gabrielle Masson
M&A
J&J pays $2.2B upfront for Ollin, taps Blackstone to fund eye disease trial
November 16, 2026
·
2 min read
·
Gabrielle Masson
Mergers & acquisitions
Lilly’s early-stage M&A quest finds $1.5B deal for Calytrix’s blood cancer work
November 16, 2026
·
1 min read
·
Annalee Armstrong